Delayed hypersensitivity to low molecular weight heparin (LMWH) in pregnancy
Heparin is currently the anticoagulant of choice for the prevention and treatment of thrombo-embolic disease in pregnancy because it does not cross the placenta . The use of low molecular weight heparin (LMWH) is preferred to unfractionated heparin (UFH) as it is associated with a lower risk of bleeding, osteoporosis, heparin induced thrombocytopenia (HIT) and hypersensitivity reactions [2, 3, 4, 5]. Fondaparinux can be considered as a valuable alternative to LMWH during pregnancy in those patients with heparin induced skin reactions and/or HIT.
Elise Schapkaitz, NHLS/WITS
barry frank jacobson, NHLS
Cite this article
South African Medical Journal 2007;97(12):1255.
Date submitted: 2007-06-18
Date published: 2007-10-17
Abstract views: 3029
Full text views: 2109
Comments on this article
*Read our policy for posting comments here